Inner Cosmos

Inner CosmosInner Cosmos
Inner Cosmos

Inner Cosmos

Developing a digital pill to rebalance brain networks using imperceptible micro-stimulations.

DR 26Speed 692019Active15San Francisco, United States
Rate

About

Inner Cosmos is developing neurotechnology to treat depression with their "Digital Pill," a minimally invasive, embedded brain-computer interface. This device reads and stimulates brain networks to restore balance, offering precision-tailored therapy that integrates seamlessly into a patient's lifestyle. Their approach aims to provide mobile therapy and eliminate the need for frequent clinic visits.
Frequently asked

What does Inner Cosmos do?

Inner Cosmos is developing neurotechnology to treat depression with their "Digital Pill," a minimally invasive, embedded brain-computer interface. This device reads and stimulates brain networks to restore balance, offering precision-tailored therapy that integrates seamlessly into a patient's lifestyle. Their approach aims to provide mobile therapy and eliminate the need for frequent clinic visits.

What is Inner Cosmos's revenue?

StartupHub estimates Inner Cosmos's annual revenue at $2.8M (range $2.2M to $5.7M, 64% confidence), based on comparable companies in the sector.

What is Inner Cosmos's valuation?

StartupHub estimates Inner Cosmos's effective valuation at $39.4M (range $25.0M to $60.0M, 10% confidence), based on comparable companies in the sector.

How much funding has Inner Cosmos raised?

Inner Cosmos has raised a total of $10M in funding. The most recent round on record is Seed.

Where is Inner Cosmos headquartered?

Inner Cosmos is headquartered in San Francisco, United States.

When was Inner Cosmos founded?

Inner Cosmos was founded in 2019.

What industry does Inner Cosmos operate in?

Inner Cosmos operates in Healthcare, Brain, Sensor, Human Machine Interface, Neurotech & HCI, MedTech.

How many employees does Inner Cosmos have?

Inner Cosmos has approximately 15 people on record.

HEADCOUNT
15
DOMAIN RATING
26
Comments

No comments yet. Be the first to share your take.